** Shares of Chinese drug producer Sichuan Kelun-Biotech Biopharmaceutical Co Ltd jump as much as 15.4% to HK$135.80, highest and biggest one-day gain since March 4
** Stock is the biggest gainer in Hang Seng Composite Index
** Co says its core product SKB264 was recently granted Breakthrough Therapy Designation by the Center for Drug Evaluation of the National Medical Products Administration (NMPA) of China for first-line treatment of breast cancer
** Co also warns of the risk that SKB264 may not ultimately be successfully developed and commercialized
** Hong Kong's healthcare index slips 0.8%, while Hang Seng Composite Index rises 0.6% and Hang Seng Index
adds 0.7%
** Stock up 30.7% YTD
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Comments